Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Giorgia Mangili has a total of 907 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Validity and responsiveness of Patient-reported outcomes Common Terminology Criteria for Adverse Events in the ovarian cancer cohort of the FICOG VIP study

    by Alice Bergamini, Piera Gargiulo, Maria Lucia Iacovino, Laura Arenare, Valentina Tuninetti, Ugo De Giorgi, Antonella Savarese, Sara Di Bella, Giorgia Mangili, Giorgio Valabrega, et al.

    Background: Use of patient-reported outcomes (PROs) is recommended by regulatory authorities for improving patient care. A multicenter Italian study tests the psychometric properties of the Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) across cancer types in Italy. Here the analysis of the ovarian cancer (OC) cohort. Methodology: A PRO-CTCAE list including 122 items (78 symptomatic adverse events [AEs]), reduced to 78 items (43 symptomatic AEs), was administered to patients with OC on anticancer treatment, at baseline (visit 1) and after 2–6 weeks (visit 2). Convergent validity with the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire - ovarian cancer module (EORTC QLQ-OV28) and Hospital Anxiety and Depression Scale (HADS) was assessed by Pearson correlation. Known-groups validity and responsiveness were tested with Eastern Cooperative Oncology Group performance status (ECOG PS 0 vs. > 0) and Patient Global Impression of Change (PGIC) scale as anchors. Results: From July 2019 to March 2024, 214 patients filled PRO-CTCAE, 210 OV28 and 209 HADS at visit 1; 192 and 182 filled PRO-CTCAE and PGIC at visit 2, respectively. Median age (IQR) was 60.8 (53.0–68.8) yrs and 88.3% had PS 0. Convergent validity analysis showed high correlation ( r ≥ 0.50) of PRO-CTCAE hot flushes, hair loss, hand/foot neuropathy, dysgeusia, bloating, abdominal pain, muscle pain, vaginal dryness, heartburn, joint pain, sadness, depression and fatigue with selected OV28 anchors. Anxiety, depression and sadness had medium to large correlation with HADS (r ranging from 0.48 to 0.66). Known-group validity showed small to large correlations (Cohen coefficients ≥ 0.20) with PS for several items. Patients classified as worsened according to the PGIC showed greater deterioration in multiple PRO-CTCAE symptom domains. Conclusions: Psychometric properties of PRO-CTCAEs indicate good construct validity and responsiveness, supporting their role in cancer care.

  • Open Access

    Management of Patients with Suspected Hypersensitivity to Chemotherapy Drugs: A Practical Approach in a Tertiary Care Setting

    by Maria Bernadette Cilona, Serena Nannipieri, Arianna Ferlito, Giulia Orsi, Monica Ronzoni, Giorgia Mangili, Emanuela Rabaiotti, Fabio Ciceri, Michele Reni, Mona-Rita Yacoub

    Background: Hypersensitivity reactions to antineoplastic agents are an increasing clinical challenge due to their rising incidence and potential severity. Early allergological assessment and tailored drug re-exposure strategies may allow continuation of essential therapies, although real-world data remain limited. Methods: We conducted a monocentric retrospective observational study including adult oncologic patients with suspected chemotherapy-induced hypersensitivity reactions. Clinical features, allergological work-up, and management strategies were analyzed. The primary outcome was the success rate of drug reintroduction using desensitization or enhanced premedication. Secondary outcomes included skin test positivity rates and the association between cumulative chemotherapy exposure and anaphylaxis. Results: Forty-two patients were included (95% female; median age 57.5 years). Re-exposure was required in 18 patients, and was successful in all patients undergoing desensitization and in 92% of those managed with enhanced premedication. Skin testing was positive in 71% of suspected platinum reactions, 30% of taxanes, and 40% of biologic agent reactions. Anaphylaxis occurred in 26.2% of patients, and a trend toward an association with cumulative chemotherapy exposure was observed; each additional cycle was associated with a 28% increase in the odds of anaphylaxis (adjusted OR 1.28; 95% CI, 1.00–1.63). Conclusions: Desensitization and enhanced premedication allow safe reintroduction of antineoplastic agents. Cumulative chemotherapy exposure is associated with an increased risk of anaphylaxis.


  • Open Access

    [18F]FDG PET/MRI in Endometrial Cancer: Prospective Evaluation of Preoperative Staging, Molecular Characterization and Prognostic Assessment

    by Carolina Bezzi, Gabriele Ironi, Tommaso Russo, Giorgio Candotti, Federico Fallanca, Carlotta Sabini, Ana Maria Samanes Gajate, Samuele Ghezzo, Alice Bergamini, Miriam Sant’angelo, et al.

    Background/Objectives: Early and accurate characterization of endometrial cancer (EC) is crucial for patient management, but current imaging modalities lack in diagnostic accuracy and ability to assess molecular profiles. The aim of this study is to evaluate hybrid [18F]FDG PET/MRI’s diagnostic accuracy in EC staging and role in predicting tumor aggressiveness, molecular characterization, and recurrence. Methods: A prospective study (ClinicalTrials.gov, ID:NCT04212910) evaluating EC patients undergoing [18F]FDG PET/MRI before surgery (2018–2024). Histology, immunohistochemistry, and patients’ follow-up (mean FU time: 3.13y) were used as the reference standard. [18F]FDG PET/MRI, PET only, and MRI only were independently reviewed to assess the diagnostic accuracy (ACC), sensitivity (SN), specificity (SP), and positive/negative predictive value (PPV, NPV). Imaging parameters were extracted from [18F]FDG PET and pcT1w, T2w, DWI, and DCE MRI. Spearman’s correlations, Fisher’s exact test, ROC-AUC analysis, Kaplan–Meier survival curves, log-rank tests and Cox proportional hazards models were applied. Results: Eighty participants with primary EC (median age 63 ± 12 years) were enrolled, with 17% showing LN involvement. [18F]FDG PET/MRI provided ACC = 98.75%, SN = 98.75%, and PPV = 100% for primary tumor detection, and ACC = 92.41%, SN = 84.62%, SP = 93.94%, PPV = 73.33%, and NPV = 96.88% for LN detection. PET/MRI parameters predicted LN involvement (AUC = 79.49%), deep myometrial invasion (79.78%), lymphovascular space invasion (82.00%), p53abn (71.47%), MMRd (74.51%), relapse (82.00%), and postoperative administration of adjuvant therapy (79.64%). Patients with a tumor cranio-caudal diameter ≥ 43 mm and MTV ≥ 13.5 cm3 showed increased probabilities of recurrence (p < 0.001). Conclusions: [18F]FDG PET/MR showed exceptional accuracy in EC primary tumor and LN detection. Derived parameters demonstrated potential ability in defining features of aggressiveness, molecular alterations, and tumor recurrence.


  • Open Access

    Can We Improve Pregnancy Rates in Hormone Receptor-Positive Breast Cancer After Endocrine Therapy? The Role of Fertility Preservation Beyond Gonadotoxic Therapy

    by Maria Vittoria Luciani, Giorgia Mangili, Enrico Papaleo, Rossella Biancardi, Valeria Stella Vanni, Rossella Masciangelo, Valentina Elisabetta Di Mattei, Massimo Candiani, Raffaella Cioffi

    Background/Objectives: Young patients with hormone receptor-positive breast cancer (HR+BC) face an elevated risk of cancer-related mortality, partly due to lower adherence to hormonal therapies for fertilities concerns. This study aims to evaluate fertility preservation in patients receiving hormonal therapy (HT) alone after surgery with or without radiotherapy. Methods: This single-center prospective cohort study evaluated BC patients counseled at the Oncofertility Unit of San Raffaele Hospital (2012–2024). Results: Of 251 BC patients who received counseling, 39 met the inclusion criteria. Among 33 patients with adequate follow-up, 15 (45.5%) are still under anticancer treatment, 6 (18.2%) completed HT but do not seek pregnancy, and 12 (36.3%) sought pregnancy, of which 9 (75%) conceived. Among the nine patients who conceived, four had completed HT (one became pregnant after thawing her cryopreserved oocytes and three had a spontaneous pregnancy). Five patients who conceived had suspended HT to seek pregnancy, according to the results of the POSITIVE trial. After HT discontinuation, all patients thawed their oocytes: three had a pregnancy with a live birth, while two patients did not conceive, so one of them attempted a new in vitro fertilization cycle achieving pregnancy with a live birth, while the other one had a spontaneous pregnancy. Conclusions: Our study highlights the importance of counseling HR+ BC patients candidates for HT alone about the efficacy and safety of fertility preservation. Offering fertility preservation can mitigate the reproductive impact of therapy-related childbearing delays and potentially improve treatment adherence.

  • Reply

    by R. Cioffi, P. I. Cavoretto, G. Mangili

  • Open Access

    Multiple pregnancy with complete hydatidiform mole and coexisting normal fetus: systematic review and meta‐analysis of clinical outcomes from non‐randomized studies

    by N. Salmeri, A. Pizzetti, E. Grassi, R. Cioffi, G. Mangili, M. Seckl, A. Sotiriadis, M. Candiani, P. I. Cavoretto

    Objective: Complete hydatidiform mole and coexisting normal fetus (CHMCF) is a rare condition for which there is significant heterogeneity in diagnosis, counseling and management of complications. The objective of this study was to summarize the prevalence of clinical outcomes in reported cases of CHMCF. Methods: A systematic literature search was conducted in PubMed, Embase and Scopus databases from inception until 1 October 2024. Case series and cohort studies including at least three cases of histologically confirmed CHMCF were included. A random‐effects model was used for meta‐analysis of proportions and heterogeneity was estimated using Higgins' I 2 index. The Newcastle–Ottawa scale and the Joanna Briggs Institute critical appraisal checklist were used to assess study quality, while certainty of evidence was assessed using Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology. The study was registered in the PROSPERO database (CRD42023431734). Results: Quantitative synthesis included 19 studies and 417 cases of CHMCF. Diagnosis was made using ultrasound in 76.0% (95% CI, 58.5–90.6%) of cases and occurred in the first trimester in 52.7% (95% CI, 34.0–71.0%). Symptoms at diagnosis were present in 80.5% (95% CI, 66.1–92.3%) of cases, with vaginal bleeding being the most common symptom both at diagnosis and later in pregnancy. The pooled proportion of elective pregnancy termination was 48.8% (95% CI, 32.7–65.1%), with 6.2% (95% CI, 1.0–13.9%) due to maternal complications. The pooled proportion of live births was 46.5% (95% CI, 36.1–57.1%), with most being delivered by Cesarean section (71.2% (95% CI, 42.4–94.4%)). Preterm birth (< 37 weeks) occurred in 67.8% (95% CI, 44.7–88.1%) of cases, very preterm birth (< 32 weeks) in 12.4% (95% CI, 0.2–33.9%) and miscarriage (fetal death < 24 weeks) in 32.7% (95% CI, 26.1–39.6%). Pre‐eclampsia was present in 17.8% (95% CI, 5.9–32.7%) of cases and postpartum hemorrhage occurred in 42.7% (95% CI, 5.1–84.8%). A small‐for‐gestational‐age neonate (birth weight < 10 th percentile) was delivered in 40.6% (95% CI, 12.9–70.8%) of cases. Rates of neonatal and maternal mortality were negligible. The pooled proportion of gestational trophoblastic neoplasia was 33.8% (95% CI, 25.6–42.5%); among elective terminations, continued pregnancies and live births, the rates were 14.1% (95% CI, 5.4–24.9%), 20.3% (95% CI, 12.0–29.9%) and 5.9% (95% CI, 1.9–11.2%), respectively. The evidence level according to GRADE was low to very low. Conclusions: Pregnancies with CHMCF present a high risk of maternal, obstetric and neonatal complications, including miscarriage, pre‐eclampsia, small‐for‐gestational age, postpartum hemorrhage and preterm birth. The risk of developing gestational trophoblastic neoplasia was not clearly mitigated by early pregnancy termination. Early diagnosis, referral to a maternal–fetal medicine unit with expertise in trophoblastic disorders and extensive implementation of screening protocols for preterm birth and pre‐eclampsia are recommended to facilitate timely intervention aimed at outcome improvement. © 2025 The Author(s). Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd on behalf of International Society of Ultrasound in Obstetrics and Gynecology.


  • Open Access

    Physicians’ Controversies Towards Fertility Preservation in Young Patients with Gynecological Cancer: An MITO Survey

    by Giacomo Corrado, Inge Peters, Erica Silvestris, Raffaella Cioffi, Marcello Iacobelli, Emanuela Mancini, Riccardo Vizza, Sofia Thiella, Gennaro Cormio, Sandro Pignata, et al.

    Guidelines on fertility preservation (FP) have been developed to help young women preserve their fertility, which may have been impaired due to cancer. Nevertheless, the correct management of oncological patients of childbearing age remains controversial, especially regarding gynecological malignancies. For this reason, we explored the current knowledge, attitudes, and clinical practices of physicians towards the challenges of FP in this population. A specially developed questionnaire on fertility-related issues in patients with gynecological cancer was administered via email to 167 people, representing 167 centers of the Multicenter Italian Trials in Ovarian cancer and gynecologic malignancies (MITO) group. A total of 56 physicians, who represented 56 out of these 167 centers, responded to our survey (response rate: 33.5%). Approximately half of these physicians stated that they had adequate knowledge about the use of gonadotropin-releasing analog (GnRHa) injections (n = 30; 53.6%), the cryopreservation of oocytes (n = 25; 44.6%), and the cryopreservation of ovarian tissue (n = 27; 48.2%) in patients with gynecological tumors. Meanwhile, regarding (borderline) ovarian tumors, endometrial or cervical cancer, and genetic mutation carriers, attitudes varied substantially. In conclusion, the results of our survey highlight the different perspectives on controversial topics among physicians directly involved in the treatment of these tumors. These findings also demonstrate the lack of evidence on these issues to adequately counsel this specific patient population.

  • Quality of radiation shapes survival, invasiveness, and migration in ovarian cancer cell lines with different molecular profiles and varying alpha/beta ratios: an in vitro study on behalf of the Multicenter Italian Trials in Ovarian Cancer (MITO) group

    by Amelia Barcellini, Alexandra Charalampopoulou, Gustavo Baldassarre, Sandro Pignata, Giorgia Mangili, Giuseppe Magro, Alessandra Dall’aCqua, Paola Tabarelli De Fatis, Giovanni Battista Ivaldi, Chiara Cassani, et al.

    The results of radiotherapy (RT) in oligometastatic ovarian cancers (OCs) lead to the query whether it is possible to stratify patients based on tumor hallmarks to ensure the best-personalized RT treatment. To address this question, we designed a preclinical study to evaluate the effects of high and low linear energy transfer (LET) radiation while considering molecular features and alpha/beta ratios of different OC cell lines. Exponentially growing human OVSAHO, OVCAR8, COV362, and OVCAR3 cells cultured in T-25 and T-75 flasks were exposed to different single physical doses of photons, protons, and carbon ion (CIRT) irradiation. We assessed ovarian cells' in vitro response using clonogenic survival (fitted using LQ model), migration by Boyden chamber assay, and invasion through BioCoat Matrigel invasion assay. Following photon irradiation, OVCAR3 was the most radioresistant and OVCAR8 the most radiosensitive cell line. OC cell migration decreased in a dose-dependent manner after irradiation, with CIRT showing the strongest effect, evident by the α/β ratio. The number of invading cells decreased following irradiation with all types. However, the greatest reduction was seen in CIRT, particularly at higher α/β ratios. Proton irradiation demonstrated similar potential to photons but did not match the effects of carbon ions in terms of survival, migration, and invasion. Conclusion: CIRT markedly reduced survival, migration, and invasion of OC cells, particularly in BRCA wild-type OVCAR3 emphasizing its potential to improve local control and lower metastasis risk. This preliminary study serves as a foundation for developing personalized clinical radiation strategies to treat oligometastatic OCs.


  • Open Access

    Additional value of uterine artery Doppler pulsatility index for ultrasound diagnosis of placental site trophoblastic tumor: prospective cohort study

    by R. Cioffi, P. I. Cavoretto, G. Sabetta, A. Bergamini, E. Rabaiotti, M. Candiani, G. Mangili

    Objectives: The ultrasound diagnosis of placental site trophoblastic tumor (PSTT) is challenging owing to a lack of pathognomonic features. Differential diagnosis from other forms of gestational trophoblastic neoplasia (GTN) is critical owing to major differences in prognosis and treatment. Doppler measurement of uterine artery (UtA) pulsatility index (PI) has been proposed for the diagnosis and management of GTN. The aim of this study was to evaluate the added value of UtA‐PI Doppler measurement during the standard transvaginal ultrasound (TVS) assessment, in patients with PSTT as compared to those with other GTN. Methods: This was a single‐center prospective cohort study involving ultrasound assessment of all GTN cases referred to and treated at the trophoblast unit of San Raffaele Hospital, Milan, Italy, between 2011 and 2023. TVS assessment included: grayscale analysis for the detection of myometrial or endometrial abnormalities, color and power Doppler assessment of lesions with scoring of vascularization, and spectral pulsed‐wave Doppler for measurement of mean UtA‐PI from the left and right UtAs. Sonographic findings were compared between patients with PSTT and those with other forms of GTN (postmolar, invasive mole or choriocarcinoma), using non‐parametric two‐tailed statistical analysis. Results: A total of 73 GTN cases were recruited, comprising nine (12.3%) with PSTT and 64 (87.7%) with other GTN. A significant difference was detected between other‐GTN and PSTT cases when comparing rates of substantial endometrial vascularity on Doppler (50% vs 0%; P = 0.013) and mean UtA‐PI measurements (median, 1.5 (interquartile range (IQR), 1.0–2.4) vs 2.2 (IQR, 1.5–2.7); P = 0.014; area under the receiver‐operating‐characteristics curve, 0.768 (95% CI, 0.610–0.888)). Conclusions: This study describes UtA‐PI as a novel and effective marker allowing for the ultrasound differentiation of PSTT from other forms of GTN. The significantly higher mean UtA‐PI and lower endometrial vascularity observed in PSTT as compared with other GTN suggests a unique vascularization pattern, with a potential role in differential diagnosis and management. © 2025 The Author(s). Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd on behalf of International Society of Ultrasound in Obstetrics and Gynecology.


  • Open Access

    Investigating the Local Effectiveness of Carbon Ion Radiotherapy for Unresectable Female Genital Tract Melanomas: A Preliminary Real-World Study

    by Amelia Barcellini, Giulia Fontana, Alessandro Vai, Giovanni Damiano Aletti, Alexandra Charalampopoulou, Silvia Chiellino, Antonino Ditto, Fabio Landoni, Laura Deborah Locati, Giorgia Mangili, et al.

    Background/Objectives: Primary gynecological melanomas are rare malignancies with lower survival rates compared to cutaneous melanomas. Both preclinical and clinical data support the evidence that mucosal melanomas are photon-radioresistant but responsive to carbon ion radiotherapy (CIRT). The aim of this study is to assess, in a real-world cohort, the effectiveness and tolerability of radical CIRT in patients with inoperable gynecological mucosal melanoma. Methods: This is a real-world study aimed to assess the effectiveness and the safety of CIRT in this setting. We defined as the primary endpoints the objective response rate (ORR) and the clinical benefit (CB). The secondary endpoints included the actuarial local control rate (LC) assessed after 1 year and 2 years and the toxicity scored according to CTCAE v.5. Actuarial outcomes were analyzed using the Kaplan–Meier method, while potential predictors were investigated through the Log-rank test. Results: Between 2017 and 2023, eleven Caucasian patients underwent pelvic CIRT (total dose 68.8 GyRBE) for mucosal malignant melanoma of the vulva or the vagina. With a median follow-up of 18 months, we observed an ORR of 82% and a CB of 100%. LC at 1 and 2 years was 100% and 86%, respectively, and among the factors analyzed for their potential impact on LC, age < 60 years seems to be a potential predictor (p = 0.014). The treatment was well tolerated, with only one case of acute grade 3 erythema and, in the late phase, one case of grade 3 erythema and grade 3 urethral toxicity. Conclusions: CIRT was effective and safe for gynecological melanomas. Larger collaborative cohort studies and longer follow-ups are needed to take a step forward in comprehending the correct management of this disease.